110409-99-9Relevant academic research and scientific papers
Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1
Kallander, Lara S.,Washburn, David,Hilfiker, Mark A.,Eidam, Hilary Schenck,Lawhorn, Brian G.,Prendergast, Joanne,Fox, Ryan,Dowdell, Sarah,Manns, Sharada,Hoang, Tram,Zhao, Steve,Ye, Guosen,Hammond, Marlys,Holt, Dennis A.,Roethke, Theresa,Hong, Xuan,Reid, Robert A.,Gampe, Robert,Zhang, Hong,Diaz, Elsie,Rendina, Alan R.,Quinn, Amy M.,Willette, Bob
, p. 736 - 740 (2018/07/25)
Bone Morphogenetic Protein 1 (BMP1) inhibition is a potential method for treating fibrosis because BMP1, a member of the zinc metalloprotease family, is required to convert pro-collagen to collagen. A novel class of reverse hydroxamate BMP1 inhibitors was
ACETOXYLATION OF 1-BENZYLOXY β-LACTAMS AT C-4 VIA A REDUCTION-OXIDATION SEQUENCE
Elburg, Paulus A. van,Reinhoudt, David N.
, p. 437 - 445 (2007/10/02)
Selective dihydroalane reduction of 1-benzyloxy β-lactams 4 affords 1-(benzyloxy)azetidines 6 which can be debenzylated to give the 1-hydroxy azetidines 7.Oxidation of the compounds 7 either gives a mixture of β-lactams 10 and 11 or selectively β-lactams
